Hudson Bay Capital Management
NSRX

Hudson Bay Capital Management’s Nasus Pharma NSRX Stock Holding History

Hudson Bay Capital Management’s Portfolio NSRX Stock Details NSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$472K Hold
134,771
– – ﹤0.01% 1012
2026
Q1 		$299K Buy
+134,771
New +$696K ﹤0.01% 1032

Other funds holding NSRX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Hudson Bay Capital Management's NSRX Position: Q2 2026 in Review

Hudson Bay Capital Management held its Nasus Pharma (NSRX) position steady in Q2 2026 at 134,771 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #1012.

Hudson Bay Capital Management first reported a position in NSRX in Q1 2026 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold NSRX as of Q2 2026.

  • Hudson Bay Capital Management held 134,771 shares of Nasus Pharma worth $472K as of Q2 2026.
  • Hudson Bay Capital Management left its Nasus Pharma share count unchanged in Q2 2026.
  • Nasus Pharma made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #1012 holding.
  • Hudson Bay Capital Management first reported a position in Nasus Pharma in Q1 2026 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held Nasus Pharma as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.